Video consultations for cancer treatment recommendations
Video-Tumorboard PLUS
This study is testing if video consultations can help patients with malignant melanoma get better treatment recommendations by connecting them with cancer experts from different specialties, no matter where they live.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital Muenster Academic / other |
| Locations | 3 sites (Bonn and 2 other locations) |
| Trial ID | NCT06980740 on ClinicalTrials.gov |
What this trial studies
This observational study aims to enhance the effectiveness of video tumor boards for patients with malignant melanoma by facilitating expert consultations across multiple specialties. The initiative seeks to ensure that patients, regardless of their geographic location, can access specialized cancer care and benefit from collective expertise in oncology. By focusing on skin cancer as a starting point, the study will evaluate how telemedicine can improve treatment recommendations for complex cases. The study includes adult patients who meet specific criteria for presentation at cancer care centers.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with malignant melanoma or other specified complex skin cancers requiring expert evaluation.
Not a fit: Patients with non-malignant conditions or those not meeting the specific eligibility criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve access to expert cancer care for patients with malignant melanoma and other complex skin cancers.
How similar studies have performed: Other studies utilizing telemedicine for cancer care have shown promising results, indicating that this approach could be beneficial for patient outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The study includes adult, external patients who, according to the certification requirements of the German Cancer Society, should be presented to the CCCs in a tumor board . Inclusion criteria for patients: * Minimum age 18 years * Consent to participate in the study (signing of patient consent) should be presented in vTB+ according to the doctor, based on the disease/diagnosis, especially in the case of: * Malignant melanoma from stage IIB * Malignant melanoma and stage shift/recurrence o Extracutaneous melanoma o Cutaneous lymphoma from stage Ib o Problem cases with malignant, epithelial tumors (BCC, SCC) with interdisciplinary issues, e.g. complicated localization, extension/ infiltration (e.g. Ulcus rodens, Ulcus terebrans), metastasized tumors, immunosuppressed patients o all rare malignant skin tumors (including Merkel cell carcinoma, DFSP, MFH, leiomyosarcoma, S., Kaposi's sarcoma, angiosarcoma), regardless of stage o severe side effects from drug-based tumor therapy • is an external patient: An external patient is someone who receives tumor therapy exclusively or in co-treatment in the branch or in an external clinic (in distinction to patients without prior treatment for initial presentation at the CCC) . This also applies to patients who are only seen once at the vTB. In this case, revenue/cost aspects and the DKG requirement are ignored. This means that so-called external patients can also be treated at the center, including initiation of therapy. The decisive factor is the presentation of the external patient (personal presentation of the external patients is not mandatory) and that external co-treaters are consistently informed and involved. Inclusion criteria for external doctors: * has a medical license * has dermatological patients who are eligible to be presented in the vTB+ Exclusion Criteria: Patients will be excluded from the study if they meet the following criteria: * Linguistic or other limitations (such as dementia) that prevent independent consent to the privacy policy. * No consent to participate in the study (patient consent) or withdrawal of consent during the course of the study In addition, external physicians will be excluded from the study if no joint cooperation agreement can be negotiated and signed.
Where this trial is running
Bonn and 2 other locations
- Abteilung für Integrierte Onkologie - CIO Bonn, Universitätsklinikum Bonn — Bonn, Germany (Not_yet_recruiting)
- Nationales Centrum für Tumorerkrankungen Klinik u. Poliklinik für Dermatologie, Universitätsklinikum Dresden — Dresden, Germany (Recruiting)
- Westdeutsches Tumorzentrum Münster, Universitätsklinikum Münster — Münster, Germany (Not_yet_recruiting)
Study contacts
- Principal investigator: Philipp Lenz, MD — Westdeutsches Tumorzentrum Münster, Universitätsklinikum Münster
- Study coordinator: Philipp Lenz, MD
- Email: philipp.lenz@ukmuenster.de
- Phone: +49 251 83 43745
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.